SCHEMBL1483160

SCHEMBL1483160

CS(=O)(=O)Nc1ccc(-c2ccc(/C=C/c3nc(-c4ccc(Cl)cc4Cl)cn3Cc3ccc(C(=O)O)cc3)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
CRHBP P24387 1/20 0.42
RAB9A P51151 1/20 0.42
CRHR2 Q13324 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLC2A2 P11168 9/20 0.39
GSK3B P49841 1/20 0.38
SRD5A2 P31213 1/20 0.37
MAPK1 P28482 1/20 0.37
ENPP2 Q13822 1/20 0.37
KIF11 P52732 1/20 0.36
PTGER1 P34995 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
GRIN1 Q05586 1/20 0.35
KCNH2 Q12809 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1483163 1.00 KDM4E (0.42) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1481195 0.96 KDM4E (0.39) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1481194 0.96 KDM4E (0.39) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1676235 0.93 SLC2A2 (0.37) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1482005 0.93 P2RX7 (0.39) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1676240 0.93 SLC2A2 (0.37) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1482001 0.93 P2RX7 (0.39) KDM4ENPC1CRHBPRAB9ACRHR2
SCHEMBL1481774 0.92 DRD2 (0.44) SLC2A2GSK3B
SCHEMBL1481778 0.92 DRD2 (0.44) SLC2A2GSK3B
SCHEMBL1481662 0.90 KDM4E (0.43) KDM4ENPC1CRHBPRAB9ACRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ KDM4E 672/4885NPC1 3792/4885CRHBP 4772/4885
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE KDM4E 733/4885NPC1 3228/4885CRHBP 4719/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE KDM4E 733/4885NPC1 3228/4885CRHBP 4719/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ KDM4E 672/4885NPC1 3792/4885CRHBP 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.